Table 2.
MMPs and TIMPs levels of the study population.
| Parameters | Non-obese (18.5 ≤ BMI < 25) | Overweight (25 ≤ BMI < 30) | Obese (BMI ≥ 30) | MHO | MetsO |
|---|---|---|---|---|---|
| MMPs | |||||
| MMP-1 (ng/ml) | 1.18 (0.04–9.97) | 1.28 (0.08–5.8) | 2.5 (0.08–22.5)* | 2.7 (0.11–14.17) | 1.84 (0.08–22.15) |
| MMP-2 (ng/ml) | 100.65 (47.56–211.43) | 117.67 (73.65–231.75)*** | 113.26 (43.98–260)* | 116.77 (43.98–260) | 110.46 (56.12–206) |
| MMP-3 (ng/ml) | 6.22 (1.28–29.66) | 9.42 (2.14–31.32) | 7.46 (1.4–33) | 7.95 (1.84–32.98) | 7.91 (1.4–23.6) |
| MMP-9 (ng/ml) | 63.02 (16.38–231.77) | 54.19 (19.76–211.34) | 66.28 (12.34–215.34) | 67.2 (15.21–215.34) | 65.72 (13.65–205.14) |
| TIMPs | |||||
| TIMP-1 (ng/ml) | 141.05 (53.34–446.21) | 173.28 (36.06–292.1) | 193.32 (53.6–487.2)***# # | 194.03 (53.62.76–413) | 184.94 (70.54–487.22) |
| TIMP-2 (ng/ml) | 90.26 (48.75–158.76) | 103.72 (77.78–190.76)** | 96.12 (65.93–268)** | 97.99 (72.44–268) | 94.47 (65.93–139.16) § |
| MMPs/TIMPs | |||||
| MMP-1/TIMP-1 | 0.007 (0.003–0.01) | 0.01 (0.005–0.01) | 0.012 (0.006–0.02) | 0.01 (0.007–0.02) | 0.01 (0.005–0.02) |
| MMP-2/TIMP-2 | 1.11 (0.56–2.5) | 1.11 (0.57–1.83) | 1.15 (0.42–1.95) | 1.12 (0.42–1.81) | 1.19 (0.54–1.95) |
| MMP-3/TIMP-1 | 0.05 (0.02–0.09) | 0.04 (0.02–0.09) | 0.03 (0.02–0.07)*** | 0.04 (0.02–0.08) | 0.04 (0.02–0.07) |
| MMP-9/TIMP-1 | 0.42 (0.09–8.61) | 0.38 (0.03–2.09) | 0.35 (0.05–1.69)* | 0.34 (0.05–1.30) | 0.39 (0.06–1.69) |
Data are presented as median (interquartile range). Statistical differences were obtained with adjusted values for age, gender, systolic blood pressure, LDL-C, TC and FG. *P < 0.05 vs non-obese. **P < 0.01 vs non-obese. ***P < 0.001 vs non-obese. #P < 0.05 vs overweight. ##P < 0.01 vs overweight. §P < 0.05 MetsO vs MHO.
MetsO Metabolic syndrome obese, MHO Metabolic healthy obese, MMP matrix metalloproteinase, TIMP tissue inhibitors of MMP.